Inovio Pharmaceuticals (STU:GBM) Cyclically Adjusted Book per Share: € (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GBM Inovio Pharmaceuticals Inc STU:GBM
48 GF Score
Price €1.07
GF Value €0.17
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Cyclically Adjusted Book per Share?

Inovio Pharmaceuticals STU:GBM +2.19% 48 Cyclically Adjusted Book per Share is € as of Jun. 2026. GuruFocus rates STU:GBM with a GF Score™ of 48/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Inovio Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2026 was €0.046. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is for the trailing ten years ended in Jun. 2026.

During the past 12 months, Inovio Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -18.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -2.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Inovio Pharmaceuticals was 4.80% per year. The lowest was -14.30% per year. And the median was -5.50% per year.

As of today (2026-09-21), Inovio Pharmaceuticals's current stock price is €1.072. Inovio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was . Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Inovio Pharmaceuticals was 18.50. The lowest was 0.04. And the median was 1.79.


Inovio Pharmaceuticals  (STU:GBM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Inovio Pharmaceuticals was 18.50. The lowest was 0.04. And the median was 1.79.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Inovio Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Inovio Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Cyclically Adjusted Book per Share Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Inovio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

STU:GBM vs HURA, VTVT, BDTX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:GBM
48GF Score
Inovio Pharmaceuticals Inc STU:GBM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inovio Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.046/333.9520*333.9520
=0.046

Current CPI (Jun. 2026) = 333.9520.

Inovio Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 21.218 241.428 29.350
201612 18.953 241.432 26.216
201703 15.928 243.801 21.818
201706 16.741 244.955 22.823
201709 18.225 246.819 24.659
201712 15.759 246.524 21.348
201803 12.166 249.554 16.280
201806 12.527 251.989 16.602
201809 11.342 252.439 15.004
201812 9.397 251.233 12.491
201903 8.835 254.202 11.607
201906 6.037 256.143 7.871
201909 4.014 256.759 5.221
201912 0.570 256.974 0.741
202003 14.080 258.115 18.217
202006 12.542 257.797 16.247
202009 19.791 260.280 25.393
202012 24.205 260.474 31.033
202103 28.368 264.877 35.766
202106 24.488 271.696 30.099
202109 22.325 274.310 27.179
202112 19.401 278.802 23.239
202203 16.907 287.504 19.638
202206 13.805 296.311 15.559
202209 13.094 296.808 14.733
202212 9.879 296.797 11.116
202303 8.375 301.836 9.266
202306 6.949 305.109 7.606
202309 5.805 307.789 6.298
202312 4.661 306.746 5.074
202403 3.742 312.332 4.001
202406 3.477 314.175 3.696
202409 2.529 315.301 2.679
202412 1.833 315.605 1.940
202503 1.294 319.799 1.351
202506 0.662 322.561 0.685
202509 -0.123 324.800 -0.126
202512 0.297 324.054 0.306
202603 0.075 330.213 0.076
202606 0.046 333.952 0.046

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of € mean?
Inovio Pharmaceuticals (STU:GBM) has a Cyclically Adjusted Book per Share of € as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Inovio Pharmaceuticals' current Cyclically Adjusted Book per Share is €. Overall, Inovio Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Cyclically Adjusted Book per Share compare to HURA and VTVT?
Inovio Pharmaceuticals' Cyclically Adjusted Book per Share of € can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Cyclically Adjusted Book per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (STU:GBM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €1.07 — trading 530.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is €. Inovio Pharmaceuticals' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Inovio Pharmaceuticals (STU:GBM), the current Cyclically Adjusted Book per Share is € as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (STU:GBM) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of €1.07 is trading 530.6% above its estimated GF Value™ of €0.17. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:GBM:

  • Cyclically Adjusted Book per Share:
  • GF Value™: €0.17 vs. price of €1.07 (530.6% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the STU:GBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inovio Pharmaceuticals Business Description

Other Exchanges INO:USAINO:Mexico0A43:UK
Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
48GF Score

Get the complete analysis for STU:GBM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.07
Price
€0.17
GF Value